Novo Nordisk A/SPartnership with H1 to leverage AI for clinical development, potentially improving efficiency and speed.

H1 has announced a new partnership with Novo Nordisk to improve clinical development using artificial intelligence. The collaboration aims to develop proprietary AI-ready data and AI-powered clinical development workflows to help Novo Nordisk speed up the path from discovery to approval and make its clinical trial operations more efficient. As part of the agreement, H1 will also acquire rights to further advance StudyHub, a leading digital and AI-enabled platform for clinical development built by Novo Nordisk. Novo Nordisk will use H1's capabilities to improve clinical development operational efficiency, with a focus on improving design, site selection and enrollment across clinical trials.
Novo Nordisk A/SPartnership with H1 to leverage AI for clinical development, potentially improving efficiency and speed.
H1 secures partnership with Novo Nordisk and acquires StudyHub, expanding its AI clinical development business.